Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer’s Disease, at Japan Neuroscience Society Special Symposium September 15, 2011
Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for Alzheimer’s Disease July 26, 2011
Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology July 25, 2011
Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease. July 16, 2011
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice. July 16, 2011
Anavex to Present at Alzheimer’s Association International Conference on Alzheimer’s Disease July 15, 2011
Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well July 6, 2011
